Hims & Hers Health (HIMS) News and press releases

How Is The Market Feeling About Hims & Hers Health?

17 Sep 24

Short Sellers, Short Ideas, Trading Ideas

Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (8 Ratings)

13 Sep 24

Analyst Ratings

B of A Securities Maintains Buy on Hims & Hers Health, Lowers Price Target to $20

13 Sep 24

News, Price Target, Analyst Ratings

B of A Securities analyst Michael Cherny maintains Hims & Hers Health (NYSE:HIMS) with a Buy and lowers the price target from $24 to $20.

Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval

11 Sep 24

Equities, News, Health Care, Markets

Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children aged 6 to 12 using the injectable pens over a year compared to a placebo group.

Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation

5 Sep 24

Biotech, Large Cap, News, Health Care, Top Stories, Media, General

Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges.

Why Hims & Hers Health Stock Is Falling

27 Aug 24

News

Eli Lilly's launch of the competitively priced Zepbound has triggered a 4.9% drop in Hims & Hers' stock. This has raised concerns over increased competition and potential market share loss.

American Woodmark Reports Downbeat Results, Joins Snowflake And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

27 Aug 24

Movers, Trading Ideas

Hims & Hers Health Sees Major Growth Opportunity In Booming Weight Loss Market, Says Analyst

22 Aug 24

Equities, Mid Cap, News, Health Care, Price Target, Initiation

Needham analyst initiates coverage on Hims & Hers Health, Inc. with a Buy rating and $24 price target. Anticipates positive impact from GLP-1 market entry and strong growth potential.

The Latest Analyst Ratings For Hims & Hers Health

22 Aug 24

Analyst Ratings

Needham Initiates Coverage On Hims & Hers Health with Buy Rating, Announces Price Target of $24

22 Aug 24

News, Price Target, Initiation, Analyst Ratings

Needham analyst Ryan MacDonald initiates coverage on Hims & Hers Health (NYSE:HIMS) with a Buy rating and announces Price Target of $24.

Looking Into Hims & Hers Health's Recent Short Interest

19 Aug 24

Short Sellers, Short Ideas, Trading Ideas

Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages

19 Aug 24

Biotech, News, Health Care, Top Stories, Media, General

Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss drugs, despite legal battles and safety concerns surrounding its non-FDA-approved alternatives.

Hims & Hers Health Unusual Options Activity For August 13

13 Aug 24

Options, Markets

Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $23

7 Aug 24

News, Price Target, Analyst Ratings

Deutsche Bank analyst George Hill maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $16 to $23.

Analyst Expectations For Hims & Hers Health's Future

6 Aug 24

Analyst Ratings

Piper Sandler Reiterates Neutral on Hims & Hers Health, Maintains $18 Price Target

6 Aug 24

News, Price Target, Reiteration, Analyst Ratings

Piper Sandler analyst Korinne Wolfmeyer reiterates Hims & Hers Health (NYSE:HIMS) with a Neutral and maintains $18 price target.

Top 10 Trending Stocks On WallStreetBets As Of August 6, 2024 (Via Swaggy Stocks)

6 Aug 24

Trading Ideas

NVDAWAYINTCAAPLMADELOTHIMSPLTRQQQTSLAData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment NVDAWAYINTCAAPLMADELOTHIMSPLTRQQQTSL

Hims & Hers Health Reports Better-Than-Expected Q2 Results: Details

5 Aug 24

Earnings, News, After-Hours Center, Movers

Hims & Hers Health reported its second-quarter financial results Monday. Here's a look at the details from the report.

Hims & Hers Health Expects Q3 Revenue Of $375M - $380M, Est $323.89M

5 Aug 24

News, Guidance

Adjusted EBITDA of $35 million to $40 million, reflecting an Adjusted EBITDA margin of 9% to 11%.

Hims & Hers Health Raises FY24 Revenue Guidance From $1.20B - $1.23B To $1.37B - $1.40B, Est $1.244B

5 Aug 24

News, Guidance

Raises full year 2024 Adjusted EBITDA guidance to a range of $140 million to $155 million

Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results

5 Aug 24

Press Releases

Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-over-year in Q2 2024 Raises full

Emerging Telemedicine Leaders: Stocks Shaping Healthcare's Digital Future

25 Jul 24

Naples, Florida--News Direct--The telemedicine market is not just growing; it's booming. Valued at USD 97.48 billion in 2022 and projected to surge to USD 430.72 billion by 2031, with a robust CAGR of 17.95%,

Pharmaceutical Industry Chief Kåre Schultz Joins Hims & Hers Board

22 Jul 24

Press Releases

Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions Hims & Hers

Hims & Hers to Announce Second Quarter 2024 Financial Results on August 5, 2024

15 Jul 24

Press Releases

Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter financial results after the market closes on Monday,

Erectile Function Vs Erectile Dysfunction: How MangoRx's (NASDAQ: MGRX) Product Sets Itself Apart and Caters to a Large Market (Pun Intended)

10 Jul 24

Detroit, Michigan--News Direct--By Meg Flippin, Benzinga Ever since the pandemic, telemedicine has been taking off, and for good reason. It's easy, convenient and increases access for people around the globe. It can